Navigation Links
Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
Date:2/1/2008

LONDON, Feb. 1 /PRNewswire/ -- Chiltern, the global contract research organization, announced today that it has acquired the business of Drug Development Solutions ('DDS'), a leading Phase 1 unit located at Ninewells Hospital and Medical School, Dundee, Scotland. Ninewells is one of the United Kingdom's major teaching hospitals. The purchase of DDS supplements Chiltern's Clinical Research Unit in Slough near London.

DDS was founded in 1982 and has completed more than 700 Phase I trials. The unit offers 42 high intensity care beds with the ability to expand these to 60 and has been ISO 9001 certified since 1997. The unit is one of a small number in the United Kingdom that is located within a major hospital that can provide emergency medical services if required. This will allow the unit to attain the higher level of voluntary accreditation available for Phase 1 units from the UK regulator, the MHRA. The unit has special expertise in first in man studies and is a world leader in systemic drug phototoxicity studies in humans.

Glenn Kerkhof, Chiltern's CEO said: "We are very pleased to have acquired DDS. This move allows us to offer leading edge Phase I services to our global client base and supplements our existing Early Phase capability and strong Phase II - IV capacities. The UK has long been a centre of excellence for Early Phase clinical pharmacology and once again offers a stable regulatory environment and internationally competitive approval timelines. We very much look forward to building on DDS' expertise and reputation for excellence in this sector. Chiltern also looks forward to developing its collaboration with Ninewells Hospital and the University of Dundee Medical School."

Dr Brian Sanderson, CEO and Medical Director of DDS, will continue to lead the Dundee unit and will work closely with Chiltern's existing Clinical Research Unit to build Chiltern's Early Phase service offering.

Brian comments: "Our unit in Dundee offers safe, efficient and high quality Early Phase trials in a teaching hospital setting. The excellent regulatory climate, with approval times of approximately 14-21 days for Phase 1 trials, facilitates the performance of first-in-man studies in the U.K. and our highly experienced hospital-based unit offers best practice in this field. Not only were DDS and Chiltern established in the same year but they also share the same core values and pedigree of excellence in clinical trials. Thus we are delighted to be joining Chiltern today and adding our Phase I expertise to Chiltern's existing Early Phase capacity, global reach and strong clinical service base."

DDS will trade as Chiltern from today.

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern employs more than 1000 people with 18 offices across the United States, Europe and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

For More Information Contact:

Catherine Lemercier Richard Baptista

Chiltern International, Inc. Chiltern International Ltd.

2111 Palomar Airport Road 171 Bath Road

Suite 200 Slough

Carlsbad Berkshire

CA 92011 SL1 4AA

USA UNITED KINGDOM

Tel: 1 (760) 707 5025 Tel: 44 (0) 1753 512 000

Fax: 1 (760) 707 5022 Fax: 44 (0) 1753 511 116

Email: Catherine.Lemercier@chiltern.com Email:

Richard.Baptista@chiltern.com

Chiltern: Understanding


'/>"/>
SOURCE Chiltern International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Marco Romano, MD Joins Chiltern as Medical Director, Europe
2. Chiltern Appoints Steve Albrecht to Support Further Expansion in Late Phase
3. Chiltern Announces Acquisition of an Independent USA Based Clinical Research Organization, Clinical Trial Management Services, Inc.
4. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
5. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
6. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
7. Good Clinical Practice Journal Awards: Winners Announced
8. First-in-the-Nation Health Care Billing Policy Announced in Minnesota
9. 2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced
10. Hospitals See Infection Rates More Than Halved, Patient Stays Shortened by 27 Percent in New Study Announced by I-Flow
11. Plenary lectures announced for worlds largest osteoporosis congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: